Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India
- 23 May 2015
- journal article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 17 (5), 1285-1304
- https://doi.org/10.1208/s12248-015-9787-8
Abstract
This article describes regulatory approaches for approval of “generic” orally inhaled drug products (OIDPs) in the United States, European Union, Brazil, China and India. While registration of a generic OIDP in any given market may require some documentation of the formulation and device similarity to the “original” product as well as comparative testing of in vitro characteristics and in vivo performance, the specific documentation approaches, tests and acceptance criteria vary by the country. This divergence is due to several factors, including unique cultural, historical, legal and economic circumstances of each region; the diverse healthcare and regulatory systems; the different definitions of key terms such as “generic” and “reference” drug; the acknowledged absence of in vitro in vivo correlations for OIDPs; and the scientific and statistical issues related to OIDP testing (such as how best to account for the batch-to-batch variability of the Reference product, whether to use average bioequivalence or population bioequivalence in the statistical analysis of results, whether to use healthy volunteers or patients for pharmacokinetic studies, and which pharmacodynamic or clinical end-points should be used). As a result of this discrepancy, there are ample opportunities for the regulatory and scientific communities around the world to collaborate in developing more consistent, better aligned, science-based approaches. Moving in that direction will require both further research and further open discussion of the pros and cons of various approaches.Keywords
This publication has 38 references indexed in Scilit:
- Effect of Device Design on the In Vitro Performance and Comparability for Capsule-Based Dry Powder InhalersThe AAPS Journal, 2012
- Effects of Device and Formulation on In Vitro Performance of Dry Powder InhalersThe AAPS Journal, 2012
- Role of Pharmacokinetics in Establishing Bioequivalence for Orally Inhaled Drug Products: Workshop Summary ReportJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2011
- Sensitive studies with a significant dose-response curve for inhaled corticosteroids to investigate equivalent relative potency are feasibleBritish Journal of Clinical Pharmacology, 2011
- Pharmacokinetic and pharmacodynamic comparison of hydrofluoroalkane and chlorofluorocarbon formulations of budesonideBritish Journal of Clinical Pharmacology, 2011
- In Vitro Considerations to Support Bioequivalence of Locally Acting Drugs in Dry Powder Inhalers for Lung DiseasesThe AAPS Journal, 2009
- Eosinophilic bronchitis in asthma: A model for establishing dose-response and relative potency of inhaled corticosteroidsJournal of Allergy and Clinical Immunology, 2006
- Bronchoprotection with formoterol via dry powder and metered-dose inhalers in patients with asthmaAnnals of Allergy, Asthma & Immunology, 2005
- Dose-response comparison of budesonide dry powder inhalers using adenosine monophosphate bronchial challengeAnnals of Allergy, Asthma & Immunology, 2005
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaThe New England Journal of Medicine, 1997